TOxicity Reduction using Proton bEam therapy for Oropharyngeal cancer
A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer
Disease site: Head and neck cancer
Treatment modality: Other: Proton beam therapy
Status: Open to recruitment
TORPEdO is a phase III, multicentre, randomised trial to assess whether intensity modulated proton therapy (IMPT) compared with intensity modulated radiotherapy treatment (IMRT) reduces toxicity in oropharyngeal squamous cell carcinoma.
183 patients will be recruited from UK sites over a 3.5 year period, with patients randomised to IMPT being treated at either The Christie NHS Foundation Trust or University College London Hospitals NHS Foundation Trust. Patients will receive treatment for 6.5 weeks, and will be followed up for a further 5 years.
Chief Investigator: Dr David Thomson, The Christie NHS Foundation Trust
ICR-CTSU Scientific Lead: Professor Emma Hall
Trial management contact: [email protected]
Sponsor: The Institute of Cancer Research
Funding: Cancer Research UK (CRUK/18/010) and The Taylor Family Foundation
View TORPEdO on the National Institute for Health Research website: NIHR - Be Part Of Research
A lay summary in plain English is available from Cancer Research UK
Publications and presentations
TORPEdO – A Phase III Trial of Intensity-modulated Proton Beam Therapy Versus Intensity-modulated Radiotherapy for Multi-toxicity Reduction in Oropharyngeal Cancer. Price J, Hall E, West C, Thomson D. Clin Oncol (R Coll Radiol). 2019 Oct 8.
Patient Involvement in the Design of a Phase III Trial Comparing Intensity-modulated Proton Therapy and Intensity-modulated Radiotherapy for Oropharyngeal Cancer. Hague C, et al. Clin Oncol (R Coll Radiol). 2018 May;30(5):274-276